CEE321

N/A

Report date: 2026/05/16 20:00:17
NMEFirst In Class

Base Information

Drug NameCEE321
Drug Alias NameCEE-321
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionJanus kinase inhibitors
TargetsJanus kinase
Therapy Area/IndicationsDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharmaceuticals Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma Ag
Active IndicationsN/A
Inactive IndicationsDermatitis, Atopic

Other Information

ATC CodeN/A
Related LinksN/A